Literature DB >> 12421687

Human complement receptor type 1 (CR1) binds to a major malarial adhesin.

Malgorzata Krych-Goldberg1, Joann M Moulds, John P Atkinson.   

Abstract

Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1), a major adhesin molecule expressed on Plasmodium-falciparum-infected erythrocytes, interacts with several receptors on endothelial cells and uninfected erythrocytes. This 'stickiness', known as rosetting, is a strategy used by the parasite to remain sequestered in the microvasculature to avoid destruction in the spleen and liver. Erythrocyte rosetting causes obstruction of the blood flow in microcapillaries. Recent data suggest a direct interaction between PfEMP1 and a functional site of complement receptor type 1 (CR1; CD35) on uninfected erythrocytes. Consistent with the hypothesis that CR1 is important in malaria pathogenesis is a 40-70-fold increase in the frequency of two CR1 blood-group antigens (at least one of which might rosette less efficiently) in malaria-exposed African populations. Furthermore, structural differences in erythrocyte CR1 between human and non-human primates are probably explained by the selective pressure of malaria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12421687     DOI: 10.1016/s1471-4914(02)02419-x

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  17 in total

Review 1.  [Search for risk genes in Alzheimer's disease].

Authors:  I Karaca; H Wagner; A Ramirez
Journal:  Nervenarzt       Date:  2017-07       Impact factor: 1.214

2.  A complement receptor-1 polymorphism with high frequency in malaria endemic regions of Asia but not Africa.

Authors:  B N Thomas; B Donvito; I Cockburn; T Fandeur; J A Rowe; J H M Cohen; J M Moulds
Journal:  Genes Immun       Date:  2005-02       Impact factor: 2.676

3.  Using mutagenesis and structural biology to map the binding site for the Plasmodium falciparum merozoite protein PfRh4 on the human immune adherence receptor.

Authors:  Hyon Ju Park; Mara Guariento; Mateusz Maciejewski; Richard Hauhart; Wai-Hong Tham; Alan F Cowman; Christoph Q Schmidt; Haydyn D T Mertens; M Kathryn Liszewski; Dennis E Hourcade; Paul N Barlow; John P Atkinson
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

4.  Backbone dynamics of complement control protein (CCP) modules reveals mobility in binding surfaces.

Authors:  Joanne M O'Leary; Krystyna Bromek; Gordon M Black; Stanislava Uhrinova; Christian Schmitz; Xuefeng Wang; Malgorzata Krych; John P Atkinson; Dusan Uhrin; Paul N Barlow
Journal:  Protein Sci       Date:  2004-05       Impact factor: 6.725

Review 5.  Alzheimer's disease risk genes and mechanisms of disease pathogenesis.

Authors:  Celeste M Karch; Alison M Goate
Journal:  Biol Psychiatry       Date:  2014-05-17       Impact factor: 13.382

6.  Complement receptor 1 and the molecular pathogenesis of malaria.

Authors:  Monika Gandhi
Journal:  Indian J Hum Genet       Date:  2007-05

7.  Association of the single-nucleotide polymorphism and haplotype of the complement receptor 1 gene with malaria.

Authors:  Yan Lan; Chuan-Dong Wei; Wen-Cheng Chen; Jun-Li Wang; Chun-Fang Wang; Guo-Gang Pan; Ye-Sheng Wei; Le-Gen Nong
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

8.  The host genetic diversity in malaria infection.

Authors:  Vitor R R de Mendonça; Marilda Souza Goncalves; Manoel Barral-Netto
Journal:  J Trop Med       Date:  2012-12-13

9.  Complement receptor 1 variants confer protection from severe malaria in Odisha, India.

Authors:  Aditya K Panda; Madhumita Panda; Rina Tripathy; Sarit S Pattanaik; Balachandran Ravindran; Bidyut K Das
Journal:  PLoS One       Date:  2012-11-13       Impact factor: 3.240

10.  Circulating Immune Complex Levels are Associated with Disease Severity and Seasonality in Children with Malaria from Mali.

Authors:  Bolaji N Thomas; Dapa A Diallo; Ghislain T Noumsi; Joann M Moulds
Journal:  Biomark Insights       Date:  2012-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.